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A 75-year-old man, who previously underwent bilateral orchiectomy due 
to uncontrolled raise of prostate-specific antigen (PSA) was treated with 
3 courses of Taxotere chemotherapy for prostate cancer. Bone scintigra-
phy revealed multiple metastatic lesions in the skull, spine, ribs, left iliac 
wing, and both humeri. He was admitted to the Oncology Institute with 
a complaint of dizziness, double vision, malaise, trismus like symptoms 
and thrombocytopenia.  Enhanced magnetic resonance imaging (MRI) 
of the brain demonstrated diffusely thickened and enhancing dura at 
the convexity of the brain. No enhancing lesions were seen in the brain 
parenchyma. Additionally, diffusely decreased T1-weighted signal was 
demonstrated in the skull bones, clivus, and cervical spine, without mass 
effect, characteristic for metastatic disease. 
Brain metastases are rare in prostate cancer and occur late in the 
course of the disease (1). They usually represent the failure of hormone-
deprivation therapy and the presence of disseminated disease. The 
leptomeninges are the most common intracranial sites of prostate cancer 
metastasis (67%) followed by cerebrum (25%), and cerebellum (8%) 
(1). Literature data showed that the average time from the diagnosis of 
prostate cancer to the occurrence of cerebral or meningeal metastatic 
disease is 60 months (2). Metastasis to the brain can occur by way of 
Batson's plexus or by direct extension from adjacent structures such as 
the sphenoid bone or sinuses (3).
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Figure 1(A) Non-enhanced transverse T1 weighted MR image 
shows diffusely low signal intensity of the skull bone marrow, 
compatible with metastatic disease; 1(B) Enhanced transverse 
T1 weighted MR shows diffusely thickened dura over cerebral 
convexities with significant uptake of contrast (arrows), 
associated with mild inhomogenous enhancement of the skull 
bone marrow
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